Research programme: NF-kappa-B pathway inhibitors - Mitsubishi Tanabe Pharma
Latest Information Update: 26 May 2010
At a glance
- Originator Mitsubishi Pharma Corporation
- Class
- Mechanism of Action NF-kappa B inhibitors; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 May 2010 Discontinued - Preclinical for Cancer in Japan (PO)
- 01 Oct 2007 Mitsubishi Pharma Corporation merged with Tanabe Seiyaku Co. Ltd to form Mitsubishi Tanabe Pharma Corporation
- 04 Dec 2006 Preclinical trials in Cancer in Japan (PO)